ALNY
Alnylam Pharmaceuticals Inc
223.90$
+1.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +118.4% | +87.9% | +48.8% | +144.0% | +105.7% | +12.3% | -13.2% | -18.3% | -28.3% | +2.0% | +46.3% | +156.7% | +28.4% | -8.9% | +58.0% | -21.1% | +52.1% | +42.2% | +6.9% | -2.7% | +8.0% | +10.7% | +17.1% | |
| – | +55.9% | +99.2% | +71.1% | +170.3% | +78.6% | +11.4% | -33.8% | +26.4% | -28.2% | -52.9% | +102.3% | +193.8% | +48.1% | -10.5% | +80.2% | -32.2% | +41.9% | +52.4% | +7.4% | -4.1% | +10.8% | +10.5% | +22.9% | |
| – | +49.9% | -12.6% | -22.3% | +712.1% | -17.8% | +82.4% | -28.3% | -45.7% | -5.9% | -26.8% | +3.4% | +41.4% | +140.6% | +7.0% | +233.3% | -34.9% | +30.2% | -9.2% | +65.1% | +5.7% | -6.2% | +18.9% | +71.5% | |
| – | +49.9% | +98.5% | +73.7% | +171.6% | +79.5% | +10.4% | -34.6% | -17.2% | -37.2% | -16.1% | +100.2% | +183.4% | +55.1% | -12.8% | +80.8% | -36.5% | +41.8% | +22.0% | +29.9% | -10.0% | +11.3% | +10.5% | +7.9% | |
| – | – | – | -35.4% | +407.2% | +31.4% | -16.8% | +44.3% | +133.6% | -89.6% | -92.9% | +3,984.6% | +840.1% | -79.2% | +181.2% | +45.7% | -44.8% | +129.3% | +1,300.6% | -67.0% | +19.8% | +37.7% | +23.6% | +91.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | +0.0% | +0.0% | +2,406,799,900.0% | +134.1% | +33.5% | +14.8% | +49.3% | -30.9% | -11.9% | +5.4% | |
| – | +804.2% | +145.9% | -9.5% | +15.1% | +13.4% | +39.0% | -4.5% | -0.2% | -19.9% | +35.2% | -16.9% | +32.2% | +27.9% | +312.0% | +58.8% | +76.3% | +32.6% | +9.4% | +7.9% | +4.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -12.2% | -26.8% | -22.4% | -49.9% | -17.9% | -21.8% | -28.0% | -38.6% | -100.0% | – | – | – | – | – | – | – | – | – | – | +163.7% | – | – | |
| – | +198.2% | -67.7% | +83.2% | +6.2% | +658.7% | +19.7% | -13.9% | -22.5% | -30.3% | -6.4% | -2.1% | -4.6% | -15.0% | +181.3% | -33.4% | +19.5% | +250.6% | +150.0% | +27.8% | +21.3% | +9.3% | +3.0% | +0.1% | |
| – | +43.8% | +71.0% | +181.1% | +24.0% | +264.1% | +19.1% | +11.3% | +109.1% | -92.2% | +166.5% | +11.4% | +77.0% | -34.9% | +210.1% | +3.0% | +22.5% | +45.2% | +66.0% | +18.9% | +10.4% | +26.0% | +22.6% | +23.6% | |
| – | – | +41.6% | +137.5% | +71.5% | -25.1% | +153.8% | -31.5% | +165.4% | +465.4% | -93.2% | -31.1% | +71.3% | +34.3% | +70.8% | -4.6% | +473.1% | -56.0% | +33.2% | +10.0% | +3.5% | -1.1% | +0.9% | +8.7% | |
| – | +124.0% | -39.7% | +117.0% | +106.8% | -6.3% | -32.4% | +762.5% | -8.5% | -71.6% | -23.8% | +33.4% | +156.3% | +11.1% | +224.4% | -47.9% | +110.6% | -16.5% | +4.2% | +41.3% | +33.6% | -43.4% | +59.3% | +30.9% | |
| – | – | +392.8% | -13.9% | +7.2% | -49.9% | – | – | – | – | – | – | – | – | – | -80.0% | +0.0% | – | – | +253.3% | +50.5% | +0.4% | +0.4% | -1.6% | |
| – | – | – | +33.9% | +225.6% | -1.0% | +1.5% | -12.0% | -11.1% | -25.4% | +13.6% | +101.7% | +246.3% | +35.1% | -27.2% | +92.0% | -26.3% | +10.5% | -29.4% | -42.1% | -126.9% | – | – | +1,076.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +184.5% | +1,160.9% | +84.7% | +45.3% | +21.2% | +6.3% | +1.4% | +1.0% | +0.9% | +18.6% | +22.4% | +20.7% | +13.1% | +1.9% | +5.8% | +11.1% | +8.6% | +5.2% | +3.0% | +2.7% | +2.6% | +2.2% | +5.5% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.